Benign prostatic hyperplasia (BPH), a common disease for elder man, is accompanied by nonmalignant growth of prostate tissues, subsequently causes hypoxia and angiogenesis. Although VEGF-related angiogenesis is one of therapeutic target of prostate cancer, there is no previous study targeting angiogenesis to treat BPH. Dihydrotestosterone (DHT)-induced expressions of vascular endothelial growth factor (VEGF) in prostate epithelial RWPE-1 cells and human umbilical vascular endothelial cells (HUVECs). The conditioned media (CM) from DHT-treated RWPE-1 cells were transferred to HUVECs. Then, 6SL inhibited the angiogenesis effect of HUVECs and in vivo study from CM from DHT-treated RWPE-1 cells. These results suggest that 6SL might be a candidate for development of novel BPH drugs.